OmniAb at LD Micro main event: royalties, scale and patience

OmniAb, at the LD Micro 20th Annual Main Event Conference on October 20, 2026, highlighted its antibody discovery platform as a long-term royalty generator. The company, which partners with 110 entities including eight of the top 10 global pharmaceutical companies, reported $52 million in cash and full-year revenue expectations of $32 million to $36 million.

OmniAb's average royalty rate is 3.4%, with a total milestone potential of over $3 billion. The company's strategy emphasizes scale and diversification, and it is approaching cash break-even. Its new xPloration instrument business, aimed at a $500 million market, is also a growth driver. Despite modest royalty revenue, management anticipates growth as more partner programs reach commercialization.